Blood test may guide smarter immunotherapy for lung cancer patients

NCT ID NCT06426511

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Apr 26, 2026 · Last updated May 24, 2026 · Updated 8 times

Summary

This study tests whether a blood test that detects tiny bits of cancer DNA can help doctors decide who needs extra immunotherapy after lung cancer surgery. About 80 adults with stage IB-IIIA non-small-cell lung cancer will receive the drug toripalimab only if the blood test shows signs of remaining cancer. The goal is to see if this personalized approach works as well as giving the drug to everyone, while possibly sparing some patients from unnecessary treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LUNG CANCER, NONSMALL CELL LUNG CANCER, NONSMALL CELL